Abstract
Glioblastoma multiforme is a frequent tumor of the central nervous system in adults. Actual treatments allow a survival time of about 15 months, calling for advanced treatments. Here nanotechnologies have allowed drugs to cross the blood brain barrier and stay in glioblastoma multiforme tissues for a prolonged period of time. Actual research focus on active targeting of drugs in the glioblastoma multiforme tissue, and tracking the biodistribution of drugs by imaging. This chapter reviews nanotechnologies for targeted delivery of drugs in glioblastoma multiforme tissues. The potential of polymeric nanoparticles in the management of malignant gliomas is also discussed, with focus on coating and functionalization to cross the blood brain barrier.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abrudan C, Florian IS, Baritchii A, Soritau O, Dreve S, Tomuleasa C, Petrushev B (2014) Assessment of temozolomide action encapsulated in chitosan and polymer nanostructures on glioblastoma cell lines. Rom Neurosurg 21(1):19–30. https://doi.org/10.2478/romneu-2014-0002
Alexandrakis G, Brown EB, Tong RT, McKee TD, Campbell RB, Boucher Y, Jain RK (2004) Two-photon fluorescence correlation microscopy reveals the two-phase nature of transport in tumors. Nat Med 10:203–207. https://doi.org/10.1038/nm981
Allard E, Jarnet D, Vessières A, Vinchon-Petit S, Jaouen G, Benoit JP, Passirani C (2010) Local delivery of ferrociphenol lipid nanocapsules followed by external radiotherapy as a synergistic treatment against intracranial 9L glioma xenograft. Pharm Res 27(1):56–64. https://doi.org/10.1007/s11095-009-0006-0
Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722. https://doi.org/10.1126/science.1168750
Batchelor TT, Sorensen AG, di Tomaso E, Zhang W-T, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen P-J, Zhu M (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95. https://doi.org/10.1016/j.ccr.2006.11.021
Behera A, Padhi S (2020) Passive and active targeting strategies for the delivery of the camptothecin anticancer drug: a review. Environ Chem Lett 18:1557–1567. https://doi.org/10.1007/s10311-020-01022-9
Behera A, Mittu B, Padhi S, Singh A (2020a) Antimicrobial efficacy of essential oil nanoemulsions. In: Dhull S, Chawla P, Kaushik R (eds) Nanotechnological approaches in food microbiology. Taylor & Francis, pp 294–309
Behera A, Mittu B, Padhi S, Patra N, Singh J (2020b) Bimetallic nanoparticles: green synthesis, applications, and future perspectives. In: Abd-Elsalam K (ed) Multifunctional hybrid nanomaterials for sustainable agri-food and ecosystems. Elsevier, pp 639–682
Behin A, Hoang-Xuan K, Carpentier AF, Delattre JY (2003) Primary brain tumours in adults. Lancet 361(9354):323–331. Lancet. https://doi.org/10.1016/S0140-6736(03)12328-8
Bennewitz MF, Saltzman WM (2009) Nanotechnology for delivery of drugs to the brain for epilepsy. Neurotherapeutics 6(2):323–336. https://doi.org/10.1016/j.nurt.2009.01.018
Binello E, Germano IM (2011) Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci 102(11):1958–1966). NIH Public Access. https://doi.org/10.1111/j.1349-7006.2011.02064.x
Blanco E, Shen H, Ferrari M (2015) Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 33:941–951. https://doi.org/10.1038/nbt.3330
Boucher Y, Baxter LT, Jain RK (1990) Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 50:4478–4484
Busquets MA, Espargaro A, Sabaté R, Estelrich J (2015) Magnetic nanoparticles cross the blood-brain barrier: when physics rises to a challenge. Nanomaterials 5(4):2231–2248. MDPI AG. https://doi.org/10.3390/nano5042231
Calvo P, Gouritin B, Chacun H, Desmaile D, D’Angelo J, Noel JP, Georgin D, Fattal E, Andreux JP, Couvreur P (2001) Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharm Res 18(8):1157–1166. https://doi.org/10.1023/A:1010931127745
Chang J, Jallouli Y, Kroubi M, Yuan XB, Feng W, Kang CS, Pu PY, Betbeder D (2009) Characterization of endocytosis of transferrin-coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 379(2):285–292. https://doi.org/10.1016/j.ijpharm.2009.04.035
Cornago M, Garcia-Alberich C, Blasco-Angulo N, Vall-llaura N, Nager M, Herreros J, Comella JX, Sanchis D, Llovera M (2014) Histone deacetylase inhibitors promote glioma cell death by G2 checkpoint abrogation leading to mitotic catastrophe. Cell Death Dis 5(10):e1435. https://doi.org/10.1038/cddis.2014.412
Cui Y, Zhang M, Zeng F, Jin H, Xu Q, Huang Y (2016) Dual-targeting magnetic PLGA nanoparticles for codelivery of paclitaxel and curcumin for brain tumor therapy. ACS Appl Mater Interfaces 8(47):32159–32169. https://doi.org/10.1021/acsami.6b10175
De Boer AG, Gaillard PJ (2007) Strategies to improve drug delivery across the blood-brain barrier. Clin Pharmacokinet 46(7):553–576. Clin Pharmacokinet. https://doi.org/10.2165/00003088-200746070-00002
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284. https://doi.org/10.1038/nrc1590
Demeule M, Regina A, Ché C, Poirier J, Nguyen T, Gabathuler R, Castaigne JP, Béliveau R (2008) Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther 324(3):1064–1072. https://doi.org/10.1124/jpet.107.131318
Ding H, Inoue S, Ljubimov AV, Patil R, Portilla-Arias J, Hu J, Konda B, Wawrowsky KA, Fujita M, Karabalin N, Sasaki T, Black KL, Holler E, Ljubimova JY (2010) Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release. Proc Natl Acad Sci U S A 107(42):18143–18148. https://doi.org/10.1073/pnas.1003919107
ELAmrawy F, Othman AA, Adkins C, Helmy A, Nounou MI (2016) Tailored nanocarriers and bioconjugates for combating glioblastoma andother brain tumors. J Cancer Metastasis Treat 2:112–122
Fernandez AP, Serrano J, Amorim MA, Pozo-Rodrigalvarez A, Martinez-Murillo R (2012) Adrenomedullin and nitric oxide: implications for the etiology and treatment of primary brain tumors. CNS Neurol Disord Drug Targets 10(7):820–833. https://doi.org/10.2174/187152711798072374
Fletcher JI, Haber M, Henderson MJ, Norris MD (2010) ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 10:147–156. https://doi.org/10.1038/nrc2789
Fornaguera C, Dols-Perez A, Calderó G, García-Celma MJ, Camarasa J, Solans C (2015) PLGA nanoparticles prepared by nano-emulsion templating using low-energy methods as efficient nanocarriers for drug delivery across the blood-brain barrier. J Control Release 211:134–143. https://doi.org/10.1016/j.jconrel.2015.06.002
Ganipineni LP, Ucakar B, Joudiou N, Riva R, Jérôme C, Gallez B, Danhier F, Préat V (2019) Paclitaxel-loaded multifunctional nanoparticles for the targeted treatment of glioblastoma. J Drug Target 27(5–6):614–623. https://doi.org/10.1080/1061186X.2019.1567738
Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, Fan L, Xi Z, Jiang X, Zhang Q (2012) Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials 33(20):5115–5123. https://doi.org/10.1016/j.biomaterials.2012.03.058
Gao H, Zhang S, Yang Z, Cao S, Jiang X, Pang Z (2014) In vitro and in vivo intracellular distribution and anti-glioblastoma effects of docetaxel-loaded nanoparticles functioned with IL-13 peptide. Int J Pharm 466(1–2):8–17. https://doi.org/10.1016/j.ijpharm.2014.03.012
Geldenhuys W, Wehrung D, Groshev A, Hirani A, Sutariya V (2015) Brain-targeted delivery of doxorubicin using glutathione-coated nanoparticles for brain cancers. Pharm Dev Technol 20(4):497–506. https://doi.org/10.3109/10837450.2014.892130
Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP–dependent transporters. Nat Rev Cancer 2:48–58. https://doi.org/10.1038/nrc706
Hassan N, Firdaus S, Padhi S, Ali A, Iqbal Z (2021) Investigating natural antibiofilm components: a new therapeutic perspective against candidal vulvovaginitis. Med Hypotheses 148:110515. https://doi.org/10.1016/j.mehy.2021.110515
Holmes D (2013) The next big things are tiny. Lancet Neurol 12(1):31. Lancet Publishing Group. https://doi.org/10.1016/S1474-4422(12)70313-7
Huynh NT, Morille M, Bejaud J, Legras P, Vessieres A, Jaouen G, Benoit JP, Passirani C (2011) Treatment of 9L gliosarcoma in rats by ferrociphenol-loaded lipid nanocapsules based on a passive targeting strategy via the EPR effect. Pharm Res 28(12):3189–3198. https://doi.org/10.1007/s11095-011-0501-y
Huynh NT, Passirani C, Allard-Vannier E, Lemaire L, Roux J, Garcion E, Vessieres A, Benoit JP (2012) Administration-dependent efficacy of ferrociphenol lipid nanocapsules for the treatment of intracranial 9L rat gliosarcoma. Int J Pharm 423(1):55–62. https://doi.org/10.1016/j.ijpharm.2011.04.037
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62. https://doi.org/10.1126/science.1104819
Jain A, Jain A, Garg NK, Tyagi RK, Singh B, Katare OP, Webster TJ, Soni V (2015) Surface engineered polymeric nanocarriers mediate the delivery of transferrin-methotrexate conjugates for an improved understanding of brain cancer. Acta Biomater 24:140–151. https://doi.org/10.1016/j.actbio.2015.06.027
Khuroo T, Verma D, Talegaonkar S, Padhi S, Panda A, Iqbal Z (2014) Topotecan–tamoxifen duple PLGA polymeric nanoparticles: investigation of in vitro, in vivo and cellular uptake potential. Int J Pharm 473:384–394. https://doi.org/10.1016/j.ijpharm.2014.07.022
Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47(1):65–81. https://doi.org/10.1016/S0169-409X(00)00122-8
Lapointe S, Perry A, Butowski NA (2018) Primary brain tumours in adults. Lancet 392(10145):432–446. Lancet Publishing Group. https://doi.org/10.1016/S0140-6736(18)30990-5
Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, Chen J, Pang Z, Wang Y, Jiang X, Yang VC, Wen L (2011) Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials 32(21):4943–4950. https://doi.org/10.1016/j.biomaterials.2011.03.031
Lollo G, Vincent M, Ullio-Gamboa G, Lemaire L, Franconi F, Couez D, Benoit JP (2015) Development of multifunctional lipid nanocapsules for the co-delivery of paclitaxel and CpG-ODN in the treatment of glioblastoma. Int J Pharm 495(2):972–980. https://doi.org/10.1016/j.ijpharm.2015.09.062
MacKenzie D (1927) A classification of the tumours of the glioma group on a histogenetic basis, with a correlated study of prognosis. By Percival Bailey and Harvey Cushing. Medium 8vo. Pp. 175, with 108 illustrations. 1926. Philadelphia, London, and Montreal: J. B. Lippinco. Br J Surg 14(55):554–555. https://doi.org/10.1002/bjs.1800145540
Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev 15(11):1311–1333. Genes Dev. https://doi.org/10.1101/gad.891601
Mahmoud BS, Alamri AH, McConville C (2020) Polymeric nanoparticles for the treatment of malignant gliomas. Cancers 12(1):1–28. https://doi.org/10.3390/cancers12010175
Maier-Hauff K, Ulrich F, Nestler D, Niehoff H, Wust P, Thiesen B, Orawa H, Budach V, Jordan A (2011) Efficacy and safety of intratumoral thermotherapy using magnetic iron-oxide nanoparticles combined with external beam radiotherapy on patients with recurrent glioblastoma multiforme. J Neuro-Oncol 103(2):317–324. https://doi.org/10.1007/s11060-010-0389-0
Malinovskaya Y, Melnikov P, Baklaushev V, Gabashvili A, Osipova N, Mantrov S, Ermolenko Y, Maksimenko O, Gorshkova M, Balabanyan V, Kreuter J, Gelperina S (2017) Delivery of doxorubicin-loaded PLGA nanoparticles into U87 human glioblastoma cells. Int J Pharm 524(1–2):77–90. https://doi.org/10.1016/j.ijpharm.2017.03.049
Mehrotra N, Tripathi RM (2015) Short interfering RNA therapeutics: Nanocarriers, prospects and limitations. IET Nanobiotechnol 9(6):386–395. Institution of Engineering and Technology. https://doi.org/10.1049/iet-nbt.2015.0018
Mei H, Shi W, Pang Z, Wang H, Lu W, Jiang X, Deng J, Guo T, Hu Y (2010) EGFP-EGF1 protein-conjugated PEG-PLA nanoparticles for tissue factor targeted drug delivery. Biomaterials 31(21):5619–5626. https://doi.org/10.1016/j.biomaterials.2010.03.055
Michael JS, Lee B-S, Zhang M, Yu JS (2018) Nanotechnology for treatment of glioblastoma multiforme. J Transl Intern Med 6(3):128–133. https://doi.org/10.2478/jtim-2018-0025
Omuro A, DeAngelis LM (2013) Glioblastoma and other malignant gliomas: a clinical review. JAMA – J Am Med Assoc 310(17):1842–1850. JAMA. https://doi.org/10.1001/jama.2013.280319
Padhi S, Behera A (2020) Nanotechnology based targeting strategies for the delivery of camptothecin. In: Ankit S, Panda Amulya K, Eric L (eds) Pharmaceutical technology for natural products delivery, impact of nanotechnology. Springer Nature, Cham, pp 243–272
Padhi S, Mirza M, Verma D, Khuroo T, Panda A, Talegaonkar S et al (2015) Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro behavior and tumor amelioration potential. Drug Del 23:2827–2837. https://doi.org/10.3109/10717544.2015.1105323
Padhi S, Kapoor R, Verma D, Panda A, Iqbal Z (2018) Formulation and optimization of topotecan nanoparticles: in vitro characterization, cytotoxicity, cellular uptake and pharmacokinetic outcomes. J Photochem Photobiol B Biol 183:222–232. https://doi.org/10.1016/j.jphotobiol.2018.04.022
Padhi S, Nayak A, Behera A (2020) Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother 131:110708. https://doi.org/10.1016/j.biopha.2020.110708
Patnaik S, Gorain B, Padhi S, Choudhury H, Gabr G, Md S et al (2021) Recent update of toxicity aspects of nanoparticulate systems for drug delivery. Eur J Pharm Biopharm 161:100–119. https://doi.org/10.1016/j.ejpb.2021.02.010
Pérez-Martínez FC, Guerra J, Posadas I, Ceña V (2011) Barriers to non-viral vector-mediated gene delivery in the nervous system. Pharm Res 28(8):1843–1858. Springer. https://doi.org/10.1007/s11095-010-0364-7
Pitorre M, Simonsson C, Bastiat G, Salomon C, Pitorre M, Simonsson C, Bastiat G, Salomon C (2020) Nanovectors for neurotherapeutic delivery Part II: polymeric nanoparticles to cite this version. In: Pillay V (ed) OMICS Advances in neurotherapeutic delivery technologies. https://www.researchgate.net/publication/308118004_Nanovectors_for_Neurotherapeutic_Delivery_Part_II_Polymeric_Nanoparticles
Ramalho MJ, Sevin E, Gosselet F, Lima J, Coelho MAN, Loureiro JA, Pereira MC (2018) Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm 545(1–2):84–92. https://doi.org/10.1016/j.ijpharm.2018.04.062
Re F, Gregori M, Masserini M (2012) Nanotechnology for neurodegenerative disorders. Maturitas 73(1):45–51. Maturitas. https://doi.org/10.1016/j.maturitas.2011.12.015
Ruggiero A, Villa CH, Bander E, Rey DA, Bergkvist M, Batt CA, Manova-Todorova K, Deen WM, Scheinberg DA, McDevitt MR (2010) Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci U S A 107(27):12369–12374. https://doi.org/10.1073/pnas.0913667107
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. https://doi.org/10.1056/NEJMoa043330
Stupp R, Tonn JC, Brada M, Pentheroudakis G (2010) High-grade malignant glioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(SUPPL. 5):190–193. https://doi.org/10.1093/annonc/mdq187
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5:219–234. https://doi.org/10.1038/nrd1984
Tian G, Yin W, Jin J, Zhang X, Xing G, Li S, Gu Z, Zhao Y (2014) Engineered design of theranostic upconversion nanoparticles for tri-modal upconversion luminescence/magnetic resonance/X-ray computed tomography imaging and targeted delivery of combined anticancer drugs. J Mater Chem B 2(10):1379–1389. https://doi.org/10.1039/c3tb21394c
Verma D, Thakur P, Padhi S, Khuroo T, Talegaonkar S, Iqbal Z (2017) Design expert assisted nanoformulation design for co-delivery of topotecan and thymoquinone: optimization, in vitro characterization and stability assessment. J Mol Liq 242:382–394. https://doi.org/10.1016/j.molliq.2017.07.002
Verreault M, Wehbe M, Strutt D, Masin D, Anantha M, Walker D, Chu F, Backstrom I, Kalra J, Waterhouse D, Yapp DT, Bally MB (2015) Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma. J Control Release 220(Pt A):348–357. https://doi.org/10.1016/j.jconrel.2015.10.053
von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BY (2017) Breaking down the barriers to precision cancer nanomedicine. Trends Biotechnol 35:159–171. https://doi.org/10.1016/j.tibtech.2016.07.006
Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015) Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200:138–157. Elsevier. https://doi.org/10.1016/j.jconrel.2014.12.030
Wu J, Lee A, Lu Y, Lee RJ (2007) Vascular targeting of doxorubicin using cationic liposomes. Int J Pharm 337:329–335. https://doi.org/10.1016/j.ijpharm.2007.01.003
Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 32(18):4293–4305. https://doi.org/10.1016/j.biomaterials.2011.02.044
Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X (2012) Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials 33(32):8167–8176. https://doi.org/10.1016/j.biomaterials.2012.07.046
Zhang B, Wang H, Liao Z, Wang Y, Hu Y, Yang J, Shen S, Chen J, Mei H, Shi W, Hu Y, Pang Z, Jiang X (2014) EGFP-EGF1-conjugated nanoparticles for targeting both neovascular and glioma cells in therapy of brain glioma. Biomaterials 35(13):4133–4145. https://doi.org/10.1016/j.biomaterials.2014.01.071
Zhang TT, Li W, Meng G, Wang P, Liao W (2016) Strategies for transporting nanoparticles across the blood-brain barrier. Biomater Sci 4(2):219–229. Royal Society of Chemistry. https://doi.org/10.1039/c5bm00383k
Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ, Piepmeier JM, Saltzman WM (2013) Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma. Proc Natl Acad Sci U S A 110(29):11751–11756. https://doi.org/10.1073/pnas.1304504110
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patil, P.H., Pardeshi, C.V., Surana, S.J. (2022). Polymeric Nanoparticles to Target Glioblastoma Tumors. In: Padhi, S., Behera, A., Lichtfouse, E. (eds) Polymeric nanoparticles for the treatment of solid tumors. Environmental Chemistry for a Sustainable World, vol 71. Springer, Cham. https://doi.org/10.1007/978-3-031-14848-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-031-14848-4_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-031-14847-7
Online ISBN: 978-3-031-14848-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)